Earnings release
Page 1
Navamedic ASA : Q1 2021 financial " In the first quarter of 2021 , we continued to deliver growth in our underlying portfolio . The rapid growth of specialty pharma product Mysimba and the consumer health products Alflorex and ThermaCare stand out as valued proofpoints of Navamedic's position in prioritized areas such as gastro , obesity and other lifestyle related issues , says Kathrine Gamborg Andreassen , Chief Executive Officer of Navamedic ASA , and continues . " The accelerated growth in these areas comes as a result of targeted investments in our platform , patient support programs , local category expertise and customer and stakeholder infrastructure . These investments will be key in 2021 as we continue to accelerate growth through launch of new products and push for growth in our existing portfolio . " Revenues in the first quarter of 2021 were NOK 58.6 million ( 55.6 million in the first quarter of 2020 ) . The gross margin was 39.6 % ( 28.3 % ) , while the EBITDA was NOK 2.6 million ( 0.7 ) . Navamedic will launch products in at least one country in each launch window going forward . The company targets 20 % annual growth from 2021 and reiterates its mid- to long - term ambition of building a NOK 500 million company with strong gross margins and underlying profitability . Navamedic is hosting a webcast presentation of the first quarter 2021 financial results , Tuesday 11 May at 08.30 CET . Due to the Covid - 19 situation , the presentation will only be held as a live webcast , on www.navamedic.com/investors/financial-results . Representatives from Navamedic will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand . EBITDA and other alternative performance measures ( APMs ) are defined and reconciled to the IFRS financial statements as a part of the APM section of the attached first quarter 2021 presentation on slide 22 . For further information , please contact : Kathrine Gamborg Andreassen , CEO , Navamedic Mobile : +47 951 78 680 E - mail : kathrine@navamedic.com Lars Hjarrand , CFO , Navamedic Mobile : +47 917 62 842